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ng author. Tel.: +33 6 7
ess: claude_carbon32@Summary This retrospective analysis was performed to determine the clinical and
bacteriologic efficacy of the ketolide antibacterial telithromycin in patients with
community-acquired pneumonia (CAP) with pneumococcal bacteremia. Patients
X13 years old with radiologically confirmed CAP and a positive blood culture for
Streptococcus pneumoniae at screening were analyzed from eight multicenter Phase
III/IV clinical trials. In four open-label, non-comparative studies, patients received
telithromycin 800mg once daily for 7–10 days. In four randomized, controlled,
double-blind, comparative studies, patients received telithromycin 800mg once
daily for 5–10 days or a comparator antimicrobial (amoxicillin 1000mg three times
daily, clarithromycin 500mg twice daily, or trovafloxacin 200mg once daily) for 7–10
days. In total, 118 patients (telithromycin, 94/1061 [8.9%]; comparator, 24/244
[9.8%]) had documented pneumococcal bacteremia. Those who were treated with
telithromycin achieved a clinical cure rate of 90.2% (74/82, per-protocol popula-
tion); S. pneumoniae was eradicated in 77/82 (93.9%) bacteremic patients who
received telithromycin and 15/19 (78.9%) comparator-treated patients. Clinical cure
was also observed among telithromycin-treated bacteremic patients who were
infected with penicillin- or erythromycin-resistant strains of S. pneumoniae (5/7 andPublished by Elsevier Ltd.
6 41 60 20.
hotmail.com (C. Carbon).
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C. Carbon et al.5788/10, respectively). In conclusion, telithromycin achieves high clinical and
bacteriologic cure rates in CAP patients with pneumococcal bacteremia.
& 2005 Published by Elsevier Ltd.Introduction
Community-acquired pneumonia (CAP) causes con-
siderable morbidity, with one of the most serious
complications being the progression to bacteremia
and further septic complications. Studies con-
ducted by Fang et al.1 established that bacteremia
occurs more frequently in patients with pneumonia
caused by Streptococcus pneumoniae (16/55 [29%])
compared with other etiologies, while work re-
ported by Bishara et al.2 confirmed that the
microorganism most frequently isolated from pa-
tients with CAP bacteremia is S. pneumoniae (46%
[n ¼ 4548]). Recent estimates suggest that the
annual incidence of pneumococcal bacteremia in
the USA is about 15–30 cases/100 000 population,
60–87% of which are associated with pneumococcal
pneumonia in adults.3 Data from some studies have
indicated that up to 50% of all patients with
bacteremic pneumococcal pneumonia may develop
complications, such as respiratory failure, menin-
gitis, pleural effusions, and empyema.4 Further-
more, mortality rates in studies of bacteremic
pneumococcal CAP patients were considerably
higher (18.6%) than in studies of hospitalized and
ambulatory patients with pneumococcal CAP
(8.1%).5 The relative risk of bacteremia is signifi-
cantly higher in young children (aged p2 years),
the elderly (aged X65 years), and those with
impaired immunity, asplenia, or comorbid condi-
tions, such as diabetes mellitus.4 Cigarette smoking
and alcohol abuse are also known risk factors for
bacteremic pneumococcal pneumonia.6–8
With the increasing shift towards outpatient
therapy, there is a growing risk that some outpatients
will have bacteremia. In a study by Campbell et al.8
of 760 patients with CAP, 43 (5.7%) patients had
positive blood cultures. However, severity of illness
as measured by Fine score9 correlated poorly with
the incidence of bacteremia in these patients. Thus,
while 32/622 (5.1%) patients in Fine classes III–V
were bacteremic, 11/138 (8.0%) patients in the
lower-risk classes (Fine classes I and II)—patients
whom physicians might be encouraged to treat on an
outpatient basis—also had positive blood cultures.
To add to this risk, the rising incidence of anti-
microbial resistance among strains of S. pneumoniae
is a growing concern. Current estimates suggest that
up to 40% of S. pneumoniae isolates worldwide showresistance to penicillin, although considerable regio-
nal variation exists.10 Resistance to macrolides
among isolates of S. pneumoniae is also increasing
worldwide,10 with the prevalence of resistance to
erythromycin exceeding the rates of penicillin
resistance in most countries.11 Emergence of pneu-
mococcal resistance to fluoroquinolones is a more
recent concern and is associated with increased use
of these agents.12,13 Thus, there is an appreciable
risk that some patients with CAP will not only be
bacteremic but will also have a resistant pathogen. If
cultures are not obtained—as is often the case with
outpatients—and if the efficacy of the prescribed
antibiotic is hampered by resistance or marginal
potency, these patients may progress to sepsis with
rapid clinical deterioration or suppurative complica-
tions. It is therefore of great importance that empiric
treatment given for CAP in the outpatient setting
provides reliable first-line efficacy.
Telithromycin is the first of a new class of
semisynthetic antibacterials—the ketolides—struc-
turally related to the macrolides, and was devel-
oped specifically to provide a spectrum of
antibacterial activity targeted for the effective
treatment of community-acquired respiratory tract
infections (RTIs) caused by either common or
atypical/intracellular pathogens. Importantly, teli-
thromycin shows potent in vitro activity against S.
pneumoniae, including strains that are resistant to
penicillin and erythromycin.14 The clinical and
bacteriologic efficacy of telithromycin in patients
with CAP has been demonstrated in eight recent
multinational Phase III/IV clinical trials15–21 (sanofi-
aventis, data on file). Data from six of these trials
have previously been assessed by Barman Balfour
and Figgitt.22 The aim of this analysis is to review
the clinical and bacteriologic efficacy of telithromy-
cin among the subset of patients with pneumococcal
bacteremia who were included in the eight trials.Methods
Patient population and design of studies
Data from eight international, multicenter Phase
III/IV clinical studies conducted between February
1998 and February 2002 were pooled and analyzed
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Four were randomized, controlled, double-blind,
comparative studies and four were of an open-
label, non-comparative design. Adolescent (13–18
years) and adult patients (418 years) with a
radiologically confirmed diagnosis of CAP and the
presence of at least two clinical signs and symp-
toms of CAP (cough, production of purulent
sputum, auscultatory findings such as rales and/or
evidence of pulmonary consolidation, dyspnea or
tachypnea, fever, elevated total peripheral white
blood cell count 410 000/mm3) were included in
the studies. In the open-label studies, all patients
received telithromycin 800mg once daily for 7–10
days. Patients in the four comparative studies were
randomized to receive either telithromycin 800mg
once daily for 5–10 days (patients in one study only
were administered telithromycin for 5 or 7 days,
and in the remaining three studies received either
10 or 7–10 days of telithromycin treatment),
or a comparator antibacterial agent (amoxicillin
1000mg three times daily, clarithromycin 500mg
twice daily, or trovafloxacin 200mg once daily) for
7–10 days.
Sputum samples and at least two sets of blood
cultures were obtained from all patients before the
start of therapy. Pathogens isolated at screening
and considered responsible for infection by the
investigator were defined as causative for infec-
tion. Patients with blood cultures positive for S.
pneumoniae at screening (with or without a sputum
sample positive for S. pneumoniae) were included
in this analysis.
The modified intent to treat (mITT) population
comprised patients with a confirmed diagnosis of
CAP who received at least one dose of study
medication; the bacteriologic modified intent to
treat (bmITT) population comprised all mITT
patients with a pathogen isolated at pretherapy/
entry that was considered to be causative by the
investigator; the bacteremic bmITT population
included patients with a positive blood culture for
S. pneumoniae at screening; the per-protocol (PPb)
population included all bacteremic bmITT patients
without major protocol violations for whom out-
come could be determined at the post-therapy/test
of cure visit.
S. pneumoniae susceptibility to telithromycin,
penicillin, and erythromycin was determined by agar
dilution and disk diffusion according to standard
NCCLS methods.23 Isolates with minimum inhibitory
concentrations (MICs) p1mg/mL were considered
susceptible to telithromycin (tentative break-
points).24 All macrolide-resistant S. pneumoniae
isolates (erythromycin MICX1mg/mL) were pro-
cessed and tested for the presence of erm(B) andmef(A) genes using a multiplex rapid-cycle polymer-
ase chain reaction (PCR) with microwell-format
probe hybridization as described previously.25Clinical and bacteriologic outcomes
In the Phase III/IV studies, clinical and bacteriologic
assessments were made at five visits: Day 1
(pretherapy/entry), Days 3–5 (on-therapy), Days
11–13 (end of therapy), Days 17–24 (post-therapy/
test of cure), and Days 31–45 (late post-therapy).
Clinical outcome was assessed by the investiga-
tor, based on clinical signs and symptoms and X-ray
findings, and classified as cure, failure, or indeter-
minate. Clinical cure was defined as the disappear-
ance or return to pre-infection state of all signs and
symptoms, together with radiologic improvement,
such that further antibacterial therapy was
unnecessary; clinical failure was defined as
unchanged or worsened symptoms, requirement
for additional antibacterial agents, or an adverse
event leading to treatment discontinuation; and
indeterminate clinical outcome was defined as
missing post-treatment information, early discon-
tinuation for reasons unrelated to study drug,
requirement for additional antibacterials for non-
lower RTI-related reasons, or identification of a
laboratory measurement fulfilling exclusion criteria
and leading to treatment discontinuation after
initiation of treatment.
In patients with bacteremia, blood cultures were
repeated at the on-therapy visit and at post-
therapy/test of cure only if the patient remained
febrile or was assessed as a clinical failure. A
satisfactory bacteriologic outcome was reported
where the infecting pathogen was either shown to
have been eradicated or where the patient’s
clinical improvement was such that a follow-up
culture was not obtained. In these latter cases, it
was presumed that the pathogen had been eradi-
cated successfully. If the bacteriologic response
could not be categorized, the outcome was classed
as indeterminate. If the infection was caused by
more than one pathogen and the bacteriologic
outcome was persistence, presumed persistence,
recurrence, or reinfection for at least one patho-
gen, the outcome was classed as unsatisfactory.
The clinical and bacteriologic efficacies of
telithromycin and comparator antibacterials were
determined in patients with documented pneumo-
coccal bacteremia in the bmITT population (pa-
tients with indeterminate responses were classified
as clinical failures) and PPb populations.
Descriptive statistics were used in this retro-
spective pooled analysis.
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Patient population
Of the 2289 patients with CAP who received
telithromycin (mITT population), 1061 had an
investigator-defined causative pathogen identified
at pretherapy/screening and were therefore in-
cluded in the bmITT population (Table 1). Of these,
94 telithromycin-treated patients (8.9%) had
documented pneumococcal bacteremia compared
with 24/244 (9.8%) comparator-treated patients
(Table 1). The greater numbers of telithromycin-
treated patients included in this analysis compared
with comparator-treated patients reflect the inclu-
sion of data from four open-label studies with
telithromycin. In the telithromycin and comparator
groups, 82 and 19 patients were evaluable in the
PPb population, respectively. In most patients, S.
pneumoniae was present as the sole pathogen; 23/
82 (28.0%) telithromycin-treated patients and 6/19
(31.6%) comparator-treated patients had mixed-
pathogen infections (additional pathogens identi-
fied in samples cultured from these patients
included Haemophilus influenzae, Moraxella catar-
rhalis, Staphylococcus aureus, and Klebsiella pneu-
moniae). Among telithromycin-treated patients
with pneumococcal bacteremia, there were 13 S.
pneumoniae isolates that were resistant to peni-
cillin and/or erythromycin (PPb population;
Table 1). Of these, three were resistant to
penicillin alone (MICX2 mg/mL), six were resistant
to erythromycin alone (MICX1 mg/mL), and four S.
pneumoniae isolates were resistant to both peni-
cillin and erythromycin. In the comparator group,
one of the bacteremias was documented as being
erythromycin resistant. All S. pneumoniae isolates
were susceptible to telithromycin (MICp1 mg/mL)
at the start of therapy.
The severity of infection was comparable be-
tween bacteremic patients and those of the overall
CAP population. Among telithromycin-treated pa-
tients in the mITT population, 50.9% had a Fine
score of I, 33.6% had a Fine score of II, and 15.5%
had a Fine score of XIII (23.1% of whom were
hospitalized); in the bacteremic bmITT population,
these values were 41.5%, 41.5%, and 17.0%,
respectively (Table 1).Clinical and bacteriologic outcomes
Patients with pneumococcal bacteremia who were
treated with telithromycin achieved clinical cure
rates of 90.2% (74/82) in the PPb population and
80.9% (76/94) in the bacteremic bmITT population.Clinical cure rates for patients with bacteremia
were numerically lower for comparator-treated
subjects (Table 2), although the small numbers
involved make statistical differentiation impossi-
ble. The clinical cure rates for telithromycin in
bacteremic patients were comparable to those
observed for the overall CAP population: 91.2%
(1755/1925) for the PPb population and 83.1%
(1902/2289) for the mITT population.
Eradication of S. pneumoniae was achieved in
77/82 (93.9%) bacteremic patients who received
telithromycin (documented eradication, n ¼ 25;
presumed eradication, n ¼ 52) and 15/19 (78.9%)
bacteremic patients who received a comparator
agent (S. pneumoniae was presumed eradicated in
all comparator-treated patients) (PPb population;
Table 2). In the overall CAP PPb population,
eradication of S. pneumoniae was observed in
305/318 (95.9%) patients treated with telithromy-
cin and 63/70 (90.0%) patients treated with
comparators. The clinical and bacteriologic success
rates among telithromycin- and comparator-
treated patients with pneumococcal bacteremia
are summarized in Table 2. Clinical cure rates were
comparable for telithromycin-treated bacteremic
patients infected with isolates of S. pneumoniae
resistant to either penicillin alone (3/3) or ery-
thromycin alone (6/6; mef(A) 3/3, erm(B) 3/3),
while 2/4 patients infected with S. pneumoniae
resistant to both penicillin and erythromycin failed
treatment.
Overall, in the PPb population, eight telithromycin-
treated patients and four comparator-treated
patients (two amoxicillin and two clarithromycin)
with bacteremia were categorized as clinical failures.
Of the eight telithromycin patients, five received
additional antibacterial treatment. Four of these five
patients received treatment with a combination of
X2 antibacterial agents (including amikacin, piper-
acillin, vancomycin, penicillin, gentamycin, cefoxi-
tin, and cefuroxime axetil) while the fifth patient was
initially treated with amoxicillin followed by
amoxicillin–clavulanate. All eight patients were sub-
sequently assessed as cured with or without addi-
tional antibacterial treatment. In all eight cases, the
blood isolates of S. pneumoniae obtained at baseline
were susceptible to telithromycin and—of the six
patients who had blood cultures repeated on-therapy
or following treatment discontinuation—only one
patient was a documented microbiologic failure. This
telithromycin-treated patient who failed microbiolo-
gically had S. pneumoniae resistant to both erythro-
mycin (MIC 4.0mg/mL) and penicillin (MIC 2.0mg/mL)
at baseline. A blood culture performed on Day 4 was
positive for S. pneumoniae and the patient had some
mild to moderate respiratory symptoms but no fever.
ARTICLE IN PRESS
Ta
b
le
1
Ke
y
p
re
th
er
ap
y/
en
tr
y
ch
ar
ac
te
ri
st
ic
s
of
p
at
ie
nt
s
w
it
h
co
m
m
un
it
y-
ac
q
ui
re
d
p
ne
um
on
ia
(C
A
P
)
b
ac
te
re
m
ia
in
ei
gh
t
Ph
as
e
III
/I
V
cl
in
ic
al
tr
ia
ls
w
ho
re
ce
iv
ed
te
li
th
ro
m
yc
in
or
a
co
m
p
ar
at
or
an
ti
b
ac
te
ri
al
.
St
ud
y
d
es
ig
n
Tr
ea
tm
en
t
re
gi
m
en
N
o.
of
p
at
ie
nt
s
(b
m
IT
T
)
N
o.
of
p
at
ie
nt
s
(b
ac
te
re
m
ic
b
m
IT
T
)
N
o.
of
p
at
ie
nt
s
w
it
h
p
en
ic
il
li
n-
an
d
/o
r
er
yt
hr
om
yc
in
-r
es
is
ta
nt
S.
pn
eu
m
on
ia
e
[b
ac
te
re
m
ic
b
m
IT
T
(P
P
b)
]
%
(n
)
of
b
ac
te
re
m
ic
b
m
IT
T
p
at
ie
nt
s
Re
fe
re
nc
e
Fi
ne
sc
or
e
X
III
y
U
nd
er
ly
in
g
ri
sk
fa
ct
or
A
ge
X
65
ye
ar
s
Sm
ok
er
C
O
P
D
D
ou
b
le
-b
li
nd
,
ra
nd
om
iz
ed
,
ac
ti
ve
-c
on
tr
ol
le
d
,
tw
o-
ar
m
,
p
ar
al
le
l-
gr
ou
p
T
EL
80
0
m
g
q
d
10
d
ay
s
62
13
2
(1
)
23
.1
(3
)
23
.1
(3
)
38
.5
(5
)
0
H
ag
b
er
g
et
al
.1
5
A
M
X
10
00
m
g
ti
d
10
d
ay
s
63
14
0
(0
)
64
.3
(9
)
21
.4
(3
)
35
.7
(5
)
7.
1
(1
)
D
ou
b
le
-b
li
nd
,
ra
nd
om
iz
ed
,
ac
ti
ve
-c
on
tr
ol
le
d
,
tw
o-
ar
m
,
p
ar
al
le
l-
gr
ou
p
T
EL
80
0
m
g
q
d
10
d
ay
s
48
5
1
(1
)
0
0
60
.0
(3
)
0
D
un
b
ar
et
al
.1
6
C
LA
50
0
m
g
b
id
10
d
ay
s
45
2
0
(0
)
50
.0
(1
)
0
0
0
D
ou
b
le
-b
li
nd
,
ra
nd
om
iz
ed
,
ac
ti
ve
-c
on
tr
ol
le
d
,
tw
o-
ar
m
,
p
ar
al
le
l-
gr
ou
p
T
EL
80
0
m
g
q
d
7–
10
d
ay
s
32
3
0
(0
)
0
0
66
.7
(2
)
0
P
ul
lm
an
et
al
.1
7
T
VA
20
0
m
g
q
d
7–
10
d
ay
s
34
2
0
(0
)
0
0
50
.0
(1
)
0
D
ou
b
le
-b
li
nd
,
ra
nd
om
iz
ed
,
ac
ti
ve
-c
on
tr
ol
le
d
,
th
re
e-
ar
m
,
p
ar
al
le
l-
gr
ou
p
T
EL
80
0
m
g
q
d
5
d
ay
s
11
1
12
0
(0
)
16
.7
(2
)
0
0
0
Te
ll
ie
r
et
al
.2
1
T
EL
80
0
m
g
q
d
7
d
ay
s
12
3
7
0
(0
)
14
.3
(1
)
0
0
0
C
LA
50
0
m
g
b
id
10
d
ay
s
10
2
6
1
(1
)
16
.7
(1
)
0
0
0
O
p
en
-l
ab
el
T
EL
80
0
m
g
q
d
7–
10
d
ay
s
67
12
3
(2
)
33
.3
(4
)
16
.7
(2
)
41
.7
(5
)
25
.0
(3
)
C
ar
b
on
et
al
.1
8
O
p
en
-l
ab
el
T
EL
80
0
m
g
q
d
7–
10
d
ay
s
98
12
3
(3
)
16
.7
(2
)
0
41
.7
(5
)
8.
3
(1
)
va
n
Re
ns
b
ur
g
et
al
.1
9
O
p
en
-l
ab
el
T
EL
80
0
m
g
q
d
7
d
ay
s
25
5
8
2
(2
)
0
0
0
0
Fo
ga
rt
y
et
al
.2
0
O
p
en
-l
ab
el
T
EL
80
0
m
g
q
d
7
d
ay
s
26
5
22
5
(4
)
18
.2
(4
)
4.
5
(1
0)
54
.5
(1
2)
0
sa
no
fi
-a
ve
nt
is
,
d
at
a
on
fi
le
To
ta
l
T
EL
10
61
94
16
(1
3)
17
.0
(1
6)
6.
4
(6
)
34
.0
(3
2)
4.
3
(4
)
A
M
X
,
am
ox
ic
il
li
n;
b
id
,
tw
ic
e
d
ai
ly
;
b
m
IT
T,
b
ac
te
ri
ol
og
ic
m
od
ifi
ed
in
te
nt
to
tr
ea
t;
C
LA
,
cl
ar
it
hr
om
yc
in
;
C
O
P
D
,
ch
ro
ni
c
ob
st
ru
ct
iv
e
p
ul
m
on
ar
y
d
is
ea
se
;
P
P
b
,
b
ac
te
ri
ol
og
ic
p
er
p
ro
to
co
l;
q
d
,
on
ce
d
ai
ly
;
T
EL
,
te
li
th
ro
m
yc
in
;
ti
d
,
th
re
e
ti
m
es
d
ai
ly
;
T
VA
,
tr
ov
afl
ox
ac
in
.

D
oe
s
no
t
in
cl
ud
e
su
b
je
ct
s
w
it
h
a
d
ia
gn
os
is
of
at
yp
ic
al
in
fe
ct
io
ns
.
y T
he
re
w
er
e
no
p
at
ie
nt
s
w
it
h
Fi
ne
sc
or
es
of
IV
or
V
in
an
y
of
th
e
st
ud
ie
s,
ex
ce
p
t
th
e
co
m
p
ar
at
or
st
ud
y
w
it
h
am
ox
ic
il
li
n
in
w
hi
ch
7.
7%
of
T
EL
p
at
ie
nt
s
an
d
14
.3
%
of
A
M
X
p
at
ie
nt
s
ha
d
a
Fi
ne
sc
or
e
of
IV
,
an
d
on
e
of
th
e
op
en
-l
ab
el
st
ud
ie
s
in
w
hi
ch
4.
5%
of
T
EL
p
at
ie
nt
s
ha
d
a
Fi
ne
sc
or
e
of
IV
.
Efficacy of telithromycin in bacteremic CAP 581
ARTICLE IN PRESS
Table 2 Clinical cure and bacteriologic eradication rates in patients with pneumococcal bacteremia associated
with community-acquired pneumonia who received telithromycin or a comparator antibacterial at the post-
therapy/test of cure visit.
Telithromycin Amoxicillin Clarithromycin Trovafloxacin All comparators pooled
n=N (%) n=N n=N n=N n=N (%)
Clinical cure
bmITT population 76/94 (80.9) 7/14 6/8 2/2 15/24 (62.5)
PPb population 74/82 (90.2) 7/9 6/8 2/2 15/19 (78.9)
Bacteriologic
eradicationy
bmITT populationz 79/94 (84.0) 8/14 6/8 2/2 16/24 (66.7)
PPb population 77/82 (93.9) 7/9 6/8 2/2 15/19 (78.9)
bmitt, bacteriologic modified intent to treat; PPb, bacteriologic per protocol.
Patients with indeterminate outcomes at the post-therapy/test of cure visit were assessed as clinical failures.
yDocumented and presumed eradication.
zPatients with indeterminate outcomes at the post-therapy/test of cure visit were assessed as bacteriologic failures.
C. Carbon et al.582The investigator switched from telithromycin to
another antibiotic regimen on Day 5 (penicillin and
cefoxitin). In the comparator PPb treatment group,
all four patients classified as treatment failures
received additional antibiotics. S. pneumoniae was
not isolated from the repeat blood culture of the
single comparator-treated patient whose blood was
re-tested.
A further 10 telithromycin- and five amoxicillin-
treated patients excluded from the PPb population,
but evaluable in the bmITT population, failed
treatment. Eight of these telithromycin-treated
patients and four amoxicillin-treated patients
received additional antibacterial therapy. None of
those patients whose blood was re-tested (six
telithromycin- and four amoxicillin-treated pa-
tients) had S. pneumoniae isolated from the repeat
blood culture.
Overall, therefore, with the exception of one
patient, none of the telithromycin-treated bac-
teremic patients (n ¼ 11) classified as treatment
failures and who had a repeat blood culture was
documented as a microbiologic failure.Discussion
In patients with CAP caused by S. pneumoniae,
there is a risk of progression to bacteremia and
septic complications.4 Evidence suggests that some
patients who present with CAP and are classified as
Fine class I or II are at measurable risk for
bacteremia.8 Based on current guidelines, cost or
other socioeconomic factors, many of these pa-tients are likely to be treated as outpatients
without blood or respiratory cultures being ob-
tained. However, as inappropriate empiric antibio-
tic treatment may significantly increase mortality
in patients with CAP bacteremia,2 it is impera-
tive that empiric treatment given for CAP in
the outpatient setting provides reliable first-line
efficacy.
The treatment of pneumococcal infections is
becoming more of a challenge due to the rising
incidence of drug-resistant strains of S. pneumo-
niae. In the past, penicillins have been the
treatment of choice for pneumococcal infections;
however, more recently, guidelines for the empiric
treatment of CAP have included macrolides as initial
therapy.26,27 The development and spread of peni-
cillin- and macrolide-resistant strains of S. pneu-
moniae, however, may limit the usefulness of
macrolide and b-lactam antibacterial agents for
empiric therapy.10,28 Plouffe et al.29 observed that,
over a 40-month period (1991–1994), the proportion
of S. pneumoniae isolates obtained from bacteremic
patients who were resistant to penicillin, ceftazi-
dime, or trimethoprim–sulfamethoxazole increased
1.5–3.5-fold. Furthermore, azalides—such as
azithromycin—may not maintain sufficiently high
plasma concentrations to adequately treat pneu-
mococcal bacteremic infection.30,31 Breakthrough
pneumococcal bacteremia was recently reported in
9.8% (4/41) of patients who had previously
been treated with azithromycin or clarithromycin
for 3–5 days. The pneumococcal strains isolated
from these four patients were all resistant to
erythromycin (MIC 8–16mg/mL) and three of the
four showed reduced susceptibility to penicillin
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through bacteremia associated with failure of
macrolide therapy have also been documented.32–37
Although many of the newer fluoroquinolones have
enhanced activity against S. pneumoniae, including
macrolide- and penicillin-resistant strains, resis-
tance to these agents has begun to emerge and is
associated with increasing use of these agents.12,13
Consequently, some of the more recent guidelines
do not support first-line use of new fluoroquinolones
in outpatients and suggest reserving their use for
more serious infections in a hospital setting.27,38
Based on a number of observational studies,39–41
combination therapy comprising a b-lactam and a
macrolide has been recommended for severely ill
CAP patients requiring hospitalization.26,27,42,43
However, monotherapy is still the preferred empiric
option for the majority of patients presenting as
outpatients with mild to moderate CAP.
The results of the present analysis indicate that
oral telithromycin therapy is effective in treating
patients with pneumococcal bacteremia, producing
a response rate (74/82 [90.2%]; PPb population) of
the same magnitude as that achieved in the overall
S. pneumoniae-infected CAP population. Further-
more, none of the eight telithromycin-treated
patients assessed as clinical failures according to
protocol criteria died and—among those whose
blood was re-tested (n ¼ 6)—S. pneumoniae was
isolated from only one patient. Approximately 16%
(13/82) of the S. pneumoniae isolates from
telithromycin-treated bacteremic patients in the
present analysis exhibited resistance to penicillin
and/or erythromycin. The response rate among
these patients (5/7 and 8/10 for penicillin- and
erythromycin-resistant strains, respectively) is en-
couraging. These response rates represent two
clinical failures as both patients had penicillin-
and erythromycin-resistant strains; indeed, one of
these patients was only categorized as a failure due
to a secondary infection with Staphylococcus
aureus isolated in the urine, and not due to S.
pneumoniae. The observation that only one
erythromycin-resistant strain was isolated from
the comparator-treated bacteremic patients is
probably related to the relatively small numbers
of patients recruited in the comparator groups.
Four of the eight trials were open-label, comprising
a single telithromycin treatment group; therefore,
the number of telithromycin-treated patients in
the analysis was much greater than that of
comparator-treated patients (2289 vs. 702).
The clinical success rate achieved with telithro-
mycin in patients with pneumococcal CAP bacter-
emia in this analysis is comparable with similar
studies using other antibacterial agents. In a studyin patients with pneumococcal CAP, the success
rate among evaluable patients whose blood cul-
tures were positive for S. pneumoniae was 83.3%
(20/24) for patients receiving the fluoroquinolone
sparfloxacin and 88.2% (15/17) for those receiving
amoxicillin at the end of treatment.44 In studies
of the fluoroquinolone levofloxacin, 90.7% (98/108)
of patients with pneumococcal bacteremia had
a successful clinical response, including 91.7%
(11/12) of patients infected with a macrolide- or
penicillin-resistant strain.45 Similarly, in studies to
evaluate the efficacy and safety of dirithromycin in
the treatment of acute bacteremic pneumonia,46
a favorable clinical response post-therapy was
observed in 90.9% (10/11) and 100% (8/8) of
pneumococcal bacteremic patients treated with
dirithromycin and erythromycin, respectively. All
isolates in this study were susceptible to erythro-
mycin.46
It should be noted that the present analysis is not
a prospective study and does not fulfill the criteria
of a formal meta-analysis. However, the similar,
standardized design of the eight studies supports
the pooling of data obtained from the relatively
small number of bacteremia cases identified across
these studies. It should also be noted that the
prevalence of underlying risk factors (including
smoking status, presence or absence of COPD, and
age X65 years) varied between the two groups of
bacteremic patients; however, the low numbers of
affected patients precluded further analysis of the
impact of these underlying risk factors on the
clinical and bacteriologic efficacy of the antibac-
terial treatment regimens. Despite these limita-
tions, the findings from this analysis illustrate there
is a risk that patients treated for mild to moderate
CAP on an outpatient basis will have bacteremia.
The 90.2% cure rate achieved with oral telithromy-
cin in these patients is encouraging. The bacter-
emic patients included in this analysis had the
advantage of close monitoring and having blood
and sputum cultures evaluated. However, in com-
munity practice CAP therapy is empiric and there-
fore needs to provide reliable, effective cover
against the likely causative pathogens—which,
increasingly, will include drug-resistant strains.Conclusion
Telithromycin—the first ketolide antibacterial to
be approved for clinical use—achieves high clinical
and bacteriologic cure rates in CAP patients with
pneumococcal bacteremia. At a dosage of 800mg
given orally once daily for 5–10 days, telithromycin
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C. Carbon et al.584provides a convenient, effective treatment option
for empiric antibacterial therapy for patients with
CAP-associated pneumococcal bacteremia.References
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